Lifeboat Foundation

Exploring the cutting edge of genetic engineering, the development of programmable recombinases and zinc finger domains is ushering in a new era of precision in DNA manipulation. These advances enable precise genomic alterations, from single nucleotide changes to the insertion of large DNA segments, potentially transforming the landscape of therapeutic gene editing and opening new possibilities in personalised medicine.

Johns Hopkins researchers have found genes associated with an important placental function tied to schizophrenia risk.

Researchers at Johns Hopkins have found that genes associated with schizophrenia risk may impact the placenta, not just the brain.

The new findings could lead to better treatments for rheumatoid arthritis, lupus and other inflammatory diseases – and may even help us slow aging.

Researchers have discovered how “leaky” mitochondria can drive harmful inflammation responsible for diseases such as lupus and rheumatoid arthritis. Scientists may be able to leverage the findings to develop better treatments for those diseases, improve our ability to fight off viruses and even slow aging.

The new discovery reveals how genetic material can escape from our cellular batteries, known as mitochondria, and prompt the body to launch a damaging immune response. By developing therapies to target this process, doctors may one day be able to stop the harmful inflammation and prevent the toll it takes on our bodies.

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhDDiscount Links: Epigenetic, Telomere Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7x…

Researchers at Virginia Commonwealth University unveiled a genetic bullseye—a key gene that plays a pivotal role in initiating a genetic domino cascade, driving bone metastasis in prostate cancer.

A key gene that fuels the molecular cascade driving prostate cancer bone metastasis progression may open avenues for targeted therapies.

Scientists have categorized different types of CRISPR systems into two classes based on how their Cas nucleases function. In class 1 (types I, III, and IV), different Cas proteins form a complex machinery to identify and cut foreign DNA; in class 2 CRISPR systems (types II, V, and VI), a single Cas protein effector recognizes and cleaves DNA.⁹

After characterizing CRISPR’s role as a defense mechanism in bacteria, researchers soon realized that they could harness this system for gene manipulation in any cell. All they needed to do was design a CRISPR gRNA sequence that bound to a specific DNA sequence and triggered the Cas nuclease, which would then cut precisely at that location. With CRISPR, researchers routinely knock out gene function by cutting out a DNA fragment, or they insert a desired genetic sequence into the genome by providing a reference DNA template along with the CRISPR components. While editing eukaryotic cells has been the focus for tackling diseases, many researchers now use CRISPR to edit bacterial communities.

“It’s almost like back to the beginning or back to the origins. There’s some irony in bringing CRISPR back to where it came from,” said Rodolphe Barrangou, a functional genomics researcher at North Carolina State University, who helped characterize the immune function of CRISPR and has been working with it for more than 20 years.

Cerebral cavernous malformations occur in 0.5% of the population; 85% are sporadic, and 15% are familial or radiation-induced. Several genetic variants, including variants in CCM, drive their development. Read the full review:

Review Article from The New England Journal of Medicine — Cavernous Malformations of the Central Nervous System.

A genetically modified cow has produced milk containing human insulin, according to a new study. The proof-of-concept achievement could be scaled up to, eventually, produce enough insulin to ensure availability and reduced cost for all diabetics requiring the life-maintaining drug.

Unable to rely on their own supply due to damaged pancreatic cells, type 1 diabetics need injectable insulin to live. As do some type 2 diabetics. The World Health Organization estimates that of those who require insulin, between 150 and 200 million people worldwide, only about half are being treated with it. Access to insulin remains inadequate in many low-and middle-income countries – and some high-income countries – and its cost and unavailability have been well-documented.

In a newly published study led by the Department of Animal Sciences in the College of Agricultural, Consumer and Environmental Sciences at the University of Illinois Urbana-Champaign and the Universidade de São Paulo, researchers say they may have developed a way of eliminating insulin scarcity and reducing its cost using cows. Yep, cows.

Some dairy farms could turn into lifesaving insulin factories.